# US 2025/0154290 A1 · Recombinant heparin-like substance and method for producing the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0154290 A1
- Document ID: US20250154290A1
- Status: Published application
- Kind: A1
- Application number: 18/838,797
- Filed: 2023-02-16
- Published: 2025-05-15
- Earliest claimed: 2022-02-17
- Assignees: Kyushu University, National University Corporation
- Applicants: Kyushu University, National University Corporation
- Inventors: Masamichi KAMIHIRA; Yoshinori KAWABE; Kyosuke AKIYAMA
- Web page: https://patentgrep.com/patent/US20250154290A1

## CPC

- C08B 37/0075: {Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof}
- C07K 14/435: from animals; from humans
- C07K 14/78: Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C12N 5/10: Cells modified by introduction of foreign genetic material
- C12N 9/10: Transferases (2.) (ribonucleases C12N9/22)
- C12P 21/02: having a known sequence of two or more amino acids, e.g. glutathione
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12P: FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE {(brewing of beer C12C; producing vinegar C12J; producing specific peptides or proteins C07K; producing enzymes C12N9/00; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; measuring or testing processes involving enzymes or microorganisms C12Q; measuring or testing processes involving nucleic acid amplification reactions C12Q1/6844; fermentation processes to form a food composition, A21 or A23; compounds in general, see the relevant compound class, e.g. C01, C07)}

## Abstract

To obtain a heparin-like substance with high biological activity (anticoagulation activity) as heparin. A method for producing a heparin-like substance is provided, which comprises the step of culturing an animal cell to which the followings are introduced to obtain a culture supernatant containing a heparin-like substance: a polynucleotide encoding glucosaminyl N-deacetylase/N-sulfotransferase (NDST2); a polynucleotide encoding heparan sulfate 3-O-sulfotransferase 1 (Hs3st1); a polynucleotide encoding the extracellular domain of syndecan (SDC); and a polynucleotide encoding 6-O-sulfotransferase.

## Claims

### Claim 1

A method for producing a heparin-like substance, the method comprising culturing an animal cell to which the followings are introduced to obtain a culture supernatant containing a heparin-like substance:
a polynucleotide encoding glucosaminyl N-deacetylase/N-sulfotransferase (NDST2);
a polynucleotide encoding heparan sulfate 3-O-sulfotransferase 1 (Hs3st1); —a polynucleotide encoding the extracellular domain of syndecan (SDC); and
a polynucleotide encoding 6-O-sulfotransferase.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the 6-O-sulfotransferase is any selected from the group consisting of heparan sulfate 6-O-sulfotransferase 1 (Hs6st1), heparan sulfate 6-O-sulfotransferase 2 (Hs6st2), and heparan sulfate 6-O-sulfotransferase 3 (Hs6st3).

### Claim 3 (depends on 1)

The method according to claim 1, wherein the 6-O-sulfotransferase is Hs6st3.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the animal cell is CHO cell.

### Claim 5 (depends on 1)

A recombinant heparin-like substance produced by the method according to claim 1, which has an anticoagulant factor Xa activity per mg of 200 IU/mg or higher.

### Claim 6

A recombinant CHO cell introduced with at least the followings:
a polynucleotide encoding NDST2;
a polynucleotide encoding Hs3st1;
a polynucleotide encoding the extracellular domain of SDC; and
a polynucleotide encoding 6-O-sulfotransferase.

### Claim 7 (depends on 6)

The cell according to claim 6, wherein the 6-O-sulfotransferase is any selected from the group consisting of Hs6st1, Hs6st2, and Hs6st3.

### Claim 8 (depends on 6)

The cell according to claim 6, wherein the 6-O-sulfotransferase is Hs6st3.

### Claim 9 (depends on 6)

The cell according to claim 6, wherein the polynucleotide encoding 6-O-sulfotransferase is any of the followings:
(A) a polynucleotide consisting of the sequence of SEQ ID NO: 29 or 43;
(B) a polynucleotide that hybridizes with a polynucleotide consisting of a sequence complementary to the sequence of SEQ ID NO: 29 or 43 under stringent conditions and encodes a protein having a function to enhance the anticoagulant factor Xa activity of a heparin-like substance produced by a heparin-like substance-producing animal cell;
(C) a polynucleotide consisting of a sequence having an identity of 90% or higher to the sequence of SEQ ID NO: 29 or 43 and encoding a protein having a function to enhance the anticoagulant factor Xa activity of a heparin-like substance produced by a heparin-like substance-producing animal cell;
(D) a polynucleotide encoding a protein consisting of the amino acid sequence of SEQ ID NO: 30 or 44;
(E) a polynucleotide encoding a protein consisting of an amino acid sequence derived from the amino acid sequence of SEQ ID NO: 30 or 44 by substitution, deletion, insertion, and/or addition of multiple amino acids and having a function to enhance the anticoagulant factor Xa activity of a heparin-like substance produced by a heparin-like substance-producing animal cell; and
(F) a polynucleotide encoding a protein consisting of an amino acid sequence having an identity of 90% or higher to the amino acid sequence of SEQ ID NO: 30 or 44 and having a function to enhance the anticoagulant factor Xa activity of a heparin-like substance produced by a heparin-like substance-producing animal cell.
